ArticleJournal of cellular and molecular medicine2026
circFOXP1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Regulating EREG/MAPK/ERK Axis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Circular RNAs (circRNAs) are indispensable for triggering pancreatic ductal adenocarcinoma (PDAC) progression. However, the specific biological processes and mechanisms by which circRNAs influence PDAC remain largely unknown. Here, we reported that circFOXP1 is a critical promoter of PDAC progression, exhibiting marked upregulation in patient tumour tissues that correlates with advanced TNM stage and poor prognosis. Functional studies demonstrate that circFOXP1 knockdown significantly suppresses PDAC cell proliferation, migration, and invasion in vitro and in vivo. Mechanistically, circFOXP1 acts as a molecular sponge for miR-320b, leading to the upregulation of epidermal growth factor receptor (EGFR) ligand Epiregulin (EREG) and the subsequent activation of the MAPK/ERK signalling pathway, which is crucial for maintaining the aggressive phenotype of PDAC. The blockade of EREG using neutralizing antibodies in vivo substantially abrogates circFOXP1-induced tumorigenesis. Our findings underscore the potential of circFOXP1 as a novel biomarker and propose a novel therapeutic target to improve survival in PDAC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.